Indaptus Therapeutics

Contributing Author

Recent Articles by Indaptus Therapeutics

Nov-17	Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit INDP GlobeNewswire
Nov-12	Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update INDP GlobeNewswire
Sep-04	Indaptus Therapeutics Provides Clinical Update INDP GlobeNewswire
Sep-02	Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference INDP GlobeNewswire
Aug-13	Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update INDP GlobeNewswire
Jul-01	Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants INDP GlobeNewswire
Jun-25	Indaptus Therapeutics Announces Reverse Stock Split INDP GlobeNewswire
Jun-13	Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants INDP GlobeNewswire
Jun-02	Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab INDP GlobeNewswire
May-14	Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update INDP GlobeNewswire
May-08	Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit INDP GlobeNewswire